June 26, 2020 / 11:48 AM / 11 days ago

BRIEF-Novartis: Cosentyx Gets Positive CHMP Opinion For Pediatric Psoriasis

June 26 (Reuters) - Novartis AG:

* NOVARTIS COSENTYX® GAINS POSITIVE CHMP OPINION FOR PEDIATRIC PSORIASIS, REINFORCING ESTABLISHED EFFICACY AND SAFETY PROFILE

* CHMP OPINION BASED ON TWO PHASE III STUDIES SHOWING COSENTYX PROVIDES FAST AND STRONG SKIN CLEARANCE AND SIGNIFICANT IMPROVEMENT IN QUALITY OF LIFE(1)

* EMA CHMP POSITIVE OPINION PAVES WAY FOR COSENTYX(®) TO BECOME A FIRST-LINE SYSTEMIC TREATMENT IN PEDIATRIC PSORIASIS Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below